Intracoronary Tirofiban on No-Reflow Phenomena

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study was to evaluate the acute effect of intracoronary administration of tirofiban on no-reflow phenomenon in patients with STEMI and occurrence of no-reflow phenomenon undergoing primary percutaneous coronary intervention (PCI).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: TC Erciyes University
• Treatments: Tirofiban

Criteria

Inclusion Criteria:

• Patients with ST-elevated myocardial infarction who developed no-reflow phenomena

Exclusion Criteria:

• Treatment with thrombolytic drugs in the previous 24 hours

• Known malignancy

• Pain to balloon time >6 hours

• Uncontrolled hypertension (>180/110 mmHg)

• Bleeding diathesis

• Thrombocytopenia

• End-stage liver disease

• Cardiogenic shock

• Renal failure

• Life expectancy of less than 1 year

• Contraindication for the use of tirofiban.